CA3110901C - Combination therapy for treating blood cancer - Google Patents
Combination therapy for treating blood cancer Download PDFInfo
- Publication number
- CA3110901C CA3110901C CA3110901A CA3110901A CA3110901C CA 3110901 C CA3110901 C CA 3110901C CA 3110901 A CA3110901 A CA 3110901A CA 3110901 A CA3110901 A CA 3110901A CA 3110901 C CA3110901 C CA 3110901C
- Authority
- CA
- Canada
- Prior art keywords
- bcl
- alkyl
- combination
- inhibitor
- axl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732816P | 2018-09-18 | 2018-09-18 | |
| US62/732,816 | 2018-09-18 | ||
| PCT/US2019/051764 WO2020061216A1 (en) | 2018-09-18 | 2019-09-18 | Combination therapy for treating blood cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3110901A1 CA3110901A1 (en) | 2020-03-26 |
| CA3110901C true CA3110901C (en) | 2024-01-02 |
Family
ID=68104787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3110901A Active CA3110901C (en) | 2018-09-18 | 2019-09-18 | Combination therapy for treating blood cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12097194B2 (https=) |
| EP (1) | EP3852766B1 (https=) |
| JP (1) | JP7460639B2 (https=) |
| KR (1) | KR102764125B1 (https=) |
| CN (1) | CN112739349B (https=) |
| AU (1) | AU2019343044B2 (https=) |
| BR (1) | BR112021005054A2 (https=) |
| CA (1) | CA3110901C (https=) |
| IL (1) | IL281439B2 (https=) |
| MX (1) | MX2021003062A (https=) |
| SG (1) | SG11202101955SA (https=) |
| TW (1) | TWI824010B (https=) |
| WO (1) | WO2020061216A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| EP3737681A4 (en) | 2018-01-10 | 2022-01-12 | Recurium IP Holdings, LLC | BENZAMIDE COMPOUNDS |
| AU2020321955A1 (en) | 2019-07-30 | 2022-03-17 | Eikonizo Therapapeutics, Inc. | HDAC6 inhibitors and uses thereof |
| MX2022005375A (es) | 2019-11-05 | 2022-10-07 | Abbvie Inc | Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con neoplasias mieloproliferativas (nmp) con navitoclax. |
| IL316201A (en) | 2022-04-08 | 2024-12-01 | Eikonizo Therapeutics Inc | Oxadiazole HDAC6 inhibitors and their uses |
| WO2025170888A1 (en) * | 2024-02-05 | 2025-08-14 | Signalchem Lifesciences Corporation | A combination of the axl inhibitor slc-391 and a pd-1 inhibitor for use in the treatment of blood cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| EP1888550B1 (en) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| SG172997A1 (en) * | 2009-01-16 | 2011-08-29 | Rigel Pharmaceuticals Inc | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
| TWI620736B (zh) | 2010-11-23 | 2018-04-11 | 艾伯維巴哈馬有限公司 | 使用選擇性ｂｃｌ-２抑制劑之治療方法 |
| WO2014020043A1 (en) * | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| JP6496731B2 (ja) * | 2013-11-27 | 2019-04-03 | シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体 |
| AU2015211021B2 (en) * | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| CN106458914B (zh) * | 2014-03-28 | 2020-01-14 | 常州捷凯医药科技有限公司 | 作为axl抑制剂的杂环化合物 |
-
2019
- 2019-09-18 US US17/276,459 patent/US12097194B2/en active Active
- 2019-09-18 BR BR112021005054-0A patent/BR112021005054A2/pt unknown
- 2019-09-18 TW TW108133696A patent/TWI824010B/zh active
- 2019-09-18 SG SG11202101955SA patent/SG11202101955SA/en unknown
- 2019-09-18 AU AU2019343044A patent/AU2019343044B2/en active Active
- 2019-09-18 IL IL281439A patent/IL281439B2/en unknown
- 2019-09-18 EP EP19780095.6A patent/EP3852766B1/en active Active
- 2019-09-18 CN CN201980060442.6A patent/CN112739349B/zh active Active
- 2019-09-18 CA CA3110901A patent/CA3110901C/en active Active
- 2019-09-18 MX MX2021003062A patent/MX2021003062A/es unknown
- 2019-09-18 WO PCT/US2019/051764 patent/WO2020061216A1/en not_active Ceased
- 2019-09-18 KR KR1020217009727A patent/KR102764125B1/ko active Active
- 2019-09-18 JP JP2021539498A patent/JP7460639B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202101955SA (en) | 2021-03-30 |
| TWI824010B (zh) | 2023-12-01 |
| WO2020061216A1 (en) | 2020-03-26 |
| KR20210061356A (ko) | 2021-05-27 |
| JP7460639B2 (ja) | 2024-04-02 |
| CN112739349B (zh) | 2024-03-01 |
| KR102764125B1 (ko) | 2025-02-07 |
| AU2019343044B2 (en) | 2025-03-06 |
| CN112739349A (zh) | 2021-04-30 |
| EP3852766B1 (en) | 2024-05-08 |
| US20220031685A1 (en) | 2022-02-03 |
| JP2022501434A (ja) | 2022-01-06 |
| IL281439B2 (en) | 2025-02-01 |
| US12097194B2 (en) | 2024-09-24 |
| MX2021003062A (es) | 2021-05-27 |
| BR112021005054A2 (pt) | 2021-06-08 |
| IL281439A (en) | 2021-04-29 |
| AU2019343044A1 (en) | 2021-03-18 |
| IL281439B1 (en) | 2024-10-01 |
| CA3110901A1 (en) | 2020-03-26 |
| TW202023554A (zh) | 2020-07-01 |
| EP3852766A1 (en) | 2021-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3110901C (en) | Combination therapy for treating blood cancer | |
| EP4129295A1 (en) | Pharmaceutical composition for prevention or treatment of cancers associated with kras mutation | |
| AU2019315487B2 (en) | Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xl dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases | |
| EP4115887A1 (en) | Pharmaceutical composition for prevention or treatment of cancer in which kras mutation and activated ron are present | |
| KR20240055778A (ko) | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 | |
| JP6568060B2 (ja) | 黒色腫の治療のための組合せ医薬 | |
| AU2017220738A1 (en) | Carboxamide derivatives useful as RSK inhibitors | |
| JP2020512343A (ja) | 血液疾患を処置するための化合物及び組成物 | |
| US12565502B2 (en) | Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | |
| BR112014021519B1 (pt) | Compostos de piperidina ou sais dos mesmos e inibidor seletivo de aurora a, composição farmacêutica, agente antitumoral e agente de potencialização de efeito antitumoral de um agonista de microtúbulos compreendendo os ditos compostos, bem como usos terapêuticos dos ditos composto | |
| Jeyapal et al. | Potential pharmacological inhibitors of Pim kinase under clinical trials | |
| CN115087463A (zh) | 并用药物 | |
| CN112237579A (zh) | 药物组合及其用途 | |
| HK40042345A (en) | Combination therapy for treating blood cancer | |
| HK40042345B (zh) | 用於治疗血癌的组合疗法 | |
| HK40035225A (en) | Pharmaceutical combination and use thereof | |
| EA050245B1 (ru) | Соединения, ингибирующие циклинзависимые киназы, для лечения нарушений состояния здоровья |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210329 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240913 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240913 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240913 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251031 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251031 |